ASN's Mission

To create a world without kidney diseases, the ASN Alliance for Kidney Health elevates care by educating and informing, driving breakthroughs and innovation, and advocating for policies that create transformative changes in kidney medicine throughout the world.

learn more

Contact ASN

1401 H St, NW, Ste 900, Washington, DC 20005

email@asn-online.org

202-640-4660

The Latest on X

Kidney Week

Abstract: FR-PO0721

Clinical Characteristics and Outcomes of Pediatric Patients with ANCA-Associated Vasculitis: Single-Center Inception Cohort

Session Information

Category: Pediatric Nephrology

  • 1900 Pediatric Nephrology

Authors

  • Lee, Michael, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Blazek, Lauren N., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Hu, Yichun, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Hogan, Susan L., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Derebail, Vimal K., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Gibson, Keisha L., The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Falk, Ronald, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
  • Wu, Eve, The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States
Background

Anti-neutrophil cytoplasmic autoantibody (ANCA)-vasculitis (AV) is a chronic autoimmune disorder characterized by small vessel inflammation and necrosis. Autoantigens include myeloperoxidase (MPO) and proteinase 3 (PR3) and mounting evidence suggests ANCA specificity better predicts prognosis than clinical phenotype. Pediatric AV is extremely rare, and treatment and prognosis are often based on adult data. We aimed to describe the clinical characteristics and outcomes by ANCA specificity.

Methods

Patients ≤18-years at AV diagnosis from the Glomerular Disease Collaborative Network were included. Key outcomes were end-stage kidney disease (ESKD), death, relapse, and remission. Baseline characteristics and treatment were analyzed in relation to outcomes. Continuous variables and categorical variables were compared using Mann-Whitney and Fisher’s exact test.

Results

We identified 88 pediatric AV patients, 36 (41%) with MPO-ANCA and 31 (35%) with PR3-ANCA. MPO-ANCA patients were younger at diagnosis (13.5 years) compared to PR3-ANCA patients (15 years). Microscopy polyangiitis (MPA) was most common (67%) among MPO-ANCA patients, and granulomatosis with polyangiitis was most common (62%) among PR3-ANCA patients (p < 0.05). All renal-limited patients were MPO-ANCA positive. A higher proportion of MPO-ANCA patients had renal involvement (97%, p <0.05), while PR3-ANCA patients had more sinus manifestations (71%, p <0.05). 33% of pediatric AV patients reached ESKD, and MPO-ANCA positivity was associated with worse kidney outcomes within 5 years of diagnosis. (Figure 1)

Conclusion

In this large, single-center cohort of pediatric AV patients, MPO-ANCA positivity was associated with younger age, MPA phenotype, and renal-limited disease. Like previously published cohorts, a significant proportion of pediatric AV patients reached ESKD, and MPO-ANCA positivity was associated with worse kidney outcomes within 5 years of diagnosis.

Digital Object Identifier (DOI)